Logan Coy Related postsA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Elritercept (KER-050) for Transfusion-Dependent Anemia in Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (RENEW)September 11, 2026A Phase 1/2a, Multicenter, Open-Label, First-in-Human Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsSeptember 11, 2026A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study of Topical HT-001 for Skin Toxicities Associated with Epidermal Growth Factor Receptor InhibitorSeptember 11, 2026 Previous postA Randomized, Multi-Center, Double-Blinded, Placebo-Controlled Trial of XEMBIFY plus Standard Medical Treatment vs Placebo to Prevent Infections in Hypogammaglobulinemia with CLL, Multiple Myeloma, and Non-Hodgkin LymphomaNext postA Phase 1b study of the pharmacokinetics, safety, and efficacy of orally administered HQP1351 in subjects with refractory chronic myeloid leukemia